Back to results
US 12,734,219 B2Granted
Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof
AssigneePeptron, Inc.
InventorsSeung Gu Chang, Jae Pyoung Cho, Ji Hyang Lee, Eun Seo Jang, Ho Il Choi
Life of this patent
Estimating the term…
Abstract
The present invention relates to sustained-release microspheres which include semaglutide or a pharmaceutically acceptable salt thereof, and a sustained-release formulation composition including the same, which enable long-term sustained release of a drug without an initial burst, and have no release delay (lag phase) while having excellent bioavailability.
Claims15
A sustained-release formulation composition, comprising:
- sustained-release microspheres which include semaglutide or a pharmaceutically acceptable salt thereof, and poly(lactide-co-glycolide);
- wherein the semaglutide or the pharmaceutically acceptable salt thereof is included in an amount of 3% by weight to 9% by weight of the sustained-release microspheres, and
- wherein the poly(lactide-co-glycolide) is a mixture of low-viscosity PLGA having an intrinsic viscosity of 0.14 to 0.24 dL/g and high-viscosity PLGA having an intrinsic viscosity of 0.32 to 0.44 dL/g.
A method for production of a sustained-release formulation composition, the method comprising:
- preparing a mixed solution by dissolving semaglutide or a pharmaceutically acceptable salt thereof and poly(lactide-co-glycolide) in an organic solvent;
- and
- drying the mixed solution to obtain microspheres,
- wherein the poly(lactide-co-glycolide) is a mixture of low-viscosity PLGA having an intrinsic viscosity of 0.14 to 0.24 dL/g and high-viscosity PLGA having an intrinsic viscosity of 0.32 to 0.44 dL/g.
1 more element
Dependencies are inferred from the claim text.